Qbrexza Availability: What Providers and Prescribers Need to Know in 2026

Qbrexza (glycopyrronium cloth, 2.4%) has been an important addition to the hyperhidrosis treatment armamentarium since its FDA approval in June 2018. As the first and only topical FDA-approved cloth for primary axillary hyperhidrosis, it represents a meaningful step between prescription-strength antiperspirants like Drysol and procedures such as Botox. However, as many prescribers have discovered, writing the prescription is only the beginning. Patient access challenges can undermine treatment initiation and adherence.

This guide provides an updated clinical and logistical overview of Qbrexza access in 2026, including the insurance landscape, available savings programs, and resources to help your patients get their prescriptions filled.

FDA Status and Supply Chain: No Current Shortage

As of 2026, Qbrexza is not listed on the FDA drug shortage database. Journey Medical Corporation continues to manufacture and distribute the product. There are no supply chain disruptions or manufacturing issues to report at this time.

The challenges patients face are not supply-side — they are commercial and structural. Prescribers should be aware of these dynamics so they can set appropriate expectations and equip their patients with the information they need to successfully fill their prescriptions.

Insurance Coverage Landscape in 2026

Coverage for Qbrexza remains inconsistent across payers in 2026:

• Commercial insurance: Coverage varies by plan and formulary. Many plans require prior authorization (PA). Step therapy requirements may mandate a trial of prescription-strength aluminum chloride (e.g., Drysol) before Qbrexza is approved. When commercial insurance covers Qbrexza, the Journey Total Access Program allows patients to pay as little as $0 at in-network pharmacies.
• Medicare Part D: Qbrexza is not commonly covered by Medicare Part D. The Journey Total Access Program and Patient Savings Card are not available to Medicare, Medicaid, or other government-program beneficiaries. These patients may need to consider alternatives or pay cash with GoodRx/SingleCare coupons (~$630–$653/month).
• Medicaid: Coverage varies by state. Many state Medicaid formularies do not include Qbrexza, or require extensive PA processes.

Prior Authorization: What You Need to Document

For plans that require prior authorization, your documentation should typically include:

• Diagnosis of primary axillary hyperhidrosis (ICD-10: L74.510)
• Documentation of prior trial and failure of prescription-strength aluminum chloride (e.g., Drysol or Xerac AC), if step therapy is required
• Severity assessment using the Hyperhidrosis Disease Severity Scale (HDSS) or equivalent clinical documentation
• Impact on quality of life, including occupational or social impairment

Some plans may also require documentation that the patient is 9 years of age or older. Journey Medical patient support at 1-855-531-1859 can assist with PA processes and provide plan-specific PA forms.

The Journey Total Access Program: How It Works for Your Patients

Journey Medical Corporation runs two parallel access programs that your commercially insured patients should know about before attempting to fill:

1. Journey Total Access Program: At in-network pharmacies listed on the getqbrexza.com pharmacy locator, commercially insured patients pay as little as $0 (if their plan covers it) or no more than $50 (if it does not). No savings card is needed at these pharmacies.
2. Qbrexza Patient Savings Card: Commercially insured patients filling at an out-of-network pharmacy whose insurance covers Qbrexza on some level can use the savings card to pay as little as $0. Available at getqbrexza.com.

Directing your patients to the pharmacy locator before they leave your office — or having your MA provide this information — can prevent the frustration of a failed first fill at a pharmacy not in the preferred network.

Pharmacy Stocking: What Your Patients May Encounter

Even at large national chain pharmacies, Qbrexza is not always kept on the shelf. Your patients may be told it's unavailable even at CVS or Walgreens locations. This is not a shortage — it's an inventory decision. Most pharmacies can special-order Qbrexza within 1–3 business days, and many in-network pharmacies can ship it directly to the patient's home.

Advising your patients that they may need to call ahead or use the pharmacy locator can reduce the number of calls your office receives about failed fills. Consider including a printed resource with your prescription that explains the Journey Total Access Program and the pharmacy locator.

How medfinder Supports Adherence for Your Patients

medfinder is a service that calls pharmacies on behalf of patients to identify which ones can fill a given prescription. For patients with Qbrexza who are struggling to locate stock, referring them to medfinder.com can eliminate the hours of calling pharmacies that often precede abandonment of a prescription. Patients provide their medication, dosage, and location; medfinder does the outreach; results are texted directly to them.

Alternatives When Qbrexza Is Not Accessible

When insurance denials are upheld on appeal or the patient is on Medicare, consider the following alternatives for primary axillary hyperhidrosis:

• Sofdra (sofpironium gel, 12.45%): FDA-approved for primary axillary hyperhidrosis in patients 9+. Topical anticholinergic; applied like a deodorant once daily.
• Botox (onabotulinumtoxinA): FDA-approved for severe primary axillary hyperhidrosis when topical therapy is inadequate. In-office injections every 4–6 months. Covered by many commercial plans with PA.
• Prescription aluminum chloride (Drysol): First-line option; well-established, inexpensive, broad formulary coverage.
• Oral glycopyrrolate or oxybutynin: Off-label; inexpensive generics; use with caution in elderly patients due to anticholinergic burden.

For additional strategies, see our companion guide: How to Help Your Patients Find Qbrexza in Stock.